Comparative Pharmacology
Head-to-head clinical analysis: KETOTIFEN FUMARATE versus TAVIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETOTIFEN FUMARATE versus TAVIST.
KETOTIFEN FUMARATE vs TAVIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine and mast cell stabilizer; inhibits release of histamine and other mediators from mast cells; also blocks histamine H1 receptors.
Antihistamine; selective inverse agonist at histamine H1 receptors, blocking histamine-mediated allergic and inflammatory responses.
1 mg orally twice daily; ophthalmic: 1 drop in each eye every 8-12 hours.
1.34 mg orally twice daily; maximum 8.04 mg/day.
None Documented
None Documented
Terminal half-life 12-24 hours (mean 18 hours); requires twice-daily dosing after initial titration.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in renal/hepatic impairment.
Renal (50-70% as conjugates, <2% unchanged), fecal (<10%), with enterohepatic circulation.
Renal excretion of metabolites (approx. 60%) and unchanged drug (<5%); biliary/fecal elimination accounts for about 40%.
Category A/B
Category C
Antihistamine / Mast Cell Stabilizer
Antihistamine